Several consumable medical devices were excluded from the list of pharmaceutical benefits by Dental and Pharmaceutical Benefit Agency

The new framework agreement on the medical devices included in the LPPR was signed on July 2, 2024.

On May 6, 2024, the Swedish Medical Technologies Product (MTP) Council commissioned the Dental and Pharmaceutical Benefits Agency (TLV) to perform a health economic evaluation of MR-guided focused ultrasound (Exablate Neuro) for the treatment of patients with essential tremor and Parkinson's disease. This evaluation is a part of the Orderly introduction framework, a staged process aimed at managing the national introduction of novel technologies. Based on the TLV assessment, the MTP Council will make recommendations to regions regarding the implementation of the technology and the criteria for use.

On March 26, 2024, the Swedish Medical Technologies Product (MTP) Council recommended three spinal cord stimulation devices (Intellis, Proclaim, and WaveWriter) for patients with neuropathic pain and insufficient effect of conventional treatment. Devices have been evaluated as part of the Orderly introduction framework.

In February 2024, the Skåne University Hospital is working on several HTAs, including evaluations in the cardiovascular, e-health, endocrine, men’s health, neurology and neurosurgery, orthopedics fields.

On January 30, 2024, the Institute for the Hospital Remuneration System (InEK) published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2023. The medical technologies of cardiovascular, ENT, extracorporeal, gastrointestinal, neuromodulation, and other technology groups obtained positive status 1.